Lunai Bioworks enters ATM sales agreement for up to $11.7M common stock offering

Lunai Bioworks Inc.

Agreement with Dawson James Securities for at-the-market offering of up to $11.7M in common stock.
Sales Agent receives 3.0% commission on gross proceeds; reimbursed for certain expenses.
Shares sold under effective S-3 registration statement (File No. 333-282898).
Company not obligated to sell any shares; may suspend or terminate at any time with 10 days' notice.
Net proceeds intended for general corporate purposes (per prospectus supplement).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lunai Bioworks Inc. entered into At-the-Market Sales Agreement with Dawson James Securities, Inc. valued at up to $11.70 million (effective 2025-12-02).

Action: entry
Agreement: atm program
Counterparty: Dawson James Securities, Inc.
Value: up to $11.70 million
Effective: 2025-12-02

Exact text from the filing

On December 2, 2025, Lunai Bioworks, Inc. (the “Company”) entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with Dawson James Securities, Inc. (the “Sales Agent”), pursuant to which the Company may offer and sell (the “Offering”) shares of its common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $11.70 million, from time to time through the Sales Agent as the Company’s sales agent.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR

accession 0001731122-25-001625

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.